Werewolf Therapeutics, Inc.

General Information

We are a preclinical biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional pro-inflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2, or IL-2, and Interleukin-12, or IL-12, respectively, INDUKINE molecules to treat solid tumors. We plan to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for WTX-124 and WTX-330 in the first half of 2022, and thereafter initiate a Phase 1/1b clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

We are building our PREDATOR platform to generate a pipeline of innovative therapeutics that cover a diversity of immune stimulating mechanisms with the potential to address significant unmet medical need in cancer.

(Note: Werewolf Therapeutics upsized its IPO at pricing on April 29, 2021, to 7.5 million shares, up from 6.25 million shares in the prospectus, at $16 – the mid-point of its $15-to-$17 range – to raise

Employees: 28
Founded: 2017
Contact Information
Address 1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138
Phone Number (617) 952-0555
Web Address http://www.werewolftx.com/
View Prospectus: Werewolf Therapeutics, Inc.
Financial Information
Market Cap $420.64mil
Revenues $0 mil (last 12 months)
Net Income $-15.04 mil (last 12 months)
IPO Profile
Symbol HOWL
Exchange NASDAQ
Shares (millions): 7.5
Price range $16.00 - $16.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Jefferies/ SVB Leerink/ Evercore
CO-Managers H.C. Wainwright & Co.
Expected To Trade: 4/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change